Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy

Acta Oncologica

Volumn 49, Issue 2, 2010, Pages 201-208

  Seol, Young Mi ^a   Kwon, Bo Ran ^a   Song, Moo Kon ^a   Choi, Young Jin ^a   Shin, Ho Jin ^a   Chung, Joo Seop ^a   Cho, Goon Jae ^a   Lee, Jin Chun ^b   Lee, Byung Joo ^b   Wang, Soo Geun ^b   Kim, Hak Jin ^b   Kim, Won Taek ^b   Kim, Seung Jang ^b   Yun, Eun Young ^a  

^a Pusan National University Hospital   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CANCER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 76649113108     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903440270     Document Type: Article

References (36)

1. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S. et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors:Relation of positron emission tomography to fl ow cytometry. J Nucl Med.1991;32:1548-1555.
2. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorooxyglucose imaging:A method to assess the proliferative activity of human cancer in vivo. Cancer.1988;61:1776-1781.
3. Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous cell carcinoma of the head and neck. J Nucl Med.7 1995;36:252-258.
4. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging:a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA fl ow cytometry in head and neck tumors. Cancer. 1988;61:1776-1781.
5. Jacob R, Welkoborsky HJ, Mann WJ, Jauch M, Amedee R. [Fluorine-18]fl uorodeoxyglucose positron emission tomography,DNA ploidy and growth fraction in squamouscell carcinomas of the head and neck. ORL J Otorhinolaryngol Relat Spec. 2001;63:307-313.
6. Minn H, Maria Lapela M, Klemi PJ. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med.2007;38:1907-1911.
7. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398-1404.
8. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
9. Roh JL, Pae KH, Choi SH, Kim JS, Lee S, Kim SB et al. 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol. 2007;33:790-795.
10. Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD et al. Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in nasopharyngeal carcinomas. Radiother Oncol.2008;87:211-216.
11. Studer G, Lutolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncologica. 2007;46:386-394.
12. Knegjens JL, Pameijer FA, Balm AJM. Tumor volume as outcome predictor in chemoradiation for advanced head and neck cancer [Abstract]. Int J Radiat Oncol Biol Phys. 2007;69(Suppl.1):S410-411.
13. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume defi nition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005;46:1342-1348.
14. Konski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G et al. The integration of 18- fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123-1128.
15. Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA et al. Detection of interval distant metastases. Clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer. 2007;109:125-134.
16. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fi ne-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg1 2005;129:1232-1241.
17. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JPA. 18F-fl uorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma:a meta-analysis. J Natl Cancer Inst. 2008;100(10):712 -720.
18. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA et al. Standardised FDG uptake:a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541.
19. Eschmann SM, Friedel G, Paulsen F, et al. Is standardized (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging. 2006;33:263-269.
20. Kieninger AN, Welsh R, Bendick PJ, Zelenock G, Chmielewski G W. Positron-emission tomography as a prognostic tool for early-stage lung cancer. Am J Surg. 2006;191:433-436.
21. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorode-oxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005;23:1136-1143.
22. Pillot G, Siegel BA, Govindan R. Prognostic significance of fl uorodeoxyglucose positron emission tomography in nonsmall cell lung cancer:a review. J Thorac Oncol. 2006;1:152-159.
23. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fl uoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295-1300.
24. Downey RJ, Akhurst T, Gonen M, Park B, Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22:3255-3260.
25. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J et al. FDG-PET prediction of head and neck squamous cell cancer out-comes. Arch Otolaryngol Head Neck Surg. 2004;130:1361-1367.
26. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer:an analysis of 125 cases. J Clin Oncol. 1999;17:3201-3206.
27. Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R et al. FDG PET studies during treatment:Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135.
28. Kim SY, Roh JL, Kim MR, et al. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med. 2007;48:752-757.
29. Greven KM, Williams DW 3rd, McGuirt WF Sr, Harkness BA, D'Agostino RB Jr, Keyes JW Jr et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck. 2001;23:942-946.
30. Vernon MR, Maheshwari M, Schultz CJ, Michel MA, Wong SJ, Campbell BH et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:678-684.
31. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys. 2004;59:1018-1026.
32. La TH, Filion EJ, Turnbull BB. Metabolic Tumor Volume Predicts for Recurrence and Death in Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2009.
33. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG et al. Metabolic tumor volume predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328-333.
34. Grow A, Quon A, Graves EE. Metabolic tumor volume as an independent prognostic factor in lymphoma. J Clin Oncol (ASCO Annual Meeting Proceedings Supplement) 2005;23:6594.
35. Chatni SS, Thankappan K. Lymph node status cannot be ignored in survival analysis of laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008 Jul;134(7):786
36. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):353-359.